Group 1 - The company, JianKai Technology, responded to investor inquiries on December 17, indicating that updates regarding the polyethylene glycol irinotecan project will be available through official company channels [1]

Core Viewpoint - The announcement details a change in equity ownership at Beijing Jiankai Technology Co., Ltd., where shareholder Wu Kaiti has reduced his stake to 15.00%, a decrease from 15.08%, through a block trade of 48,200 shares, fulfilling a previously disclosed reduction plan without triggering a mandatory bid [2][11]. Summary by Sections 1. Basic Situation of Equity Change - Wu Kaiti's shareholding decreased from 9,145,847 shares (15.08%) to 9,097,647 shares (15.00%) following the sale of 48,200 shares on December 8, 2025 [2][11]. 2. Subsequent Matters - The equity change is part of Wu Kaiti's previously disclosed reduction plan and does not affect the company's controlling shareholder or governance structure [3][4]. 3. Purpose and Future Plans - The equity change is aimed at fulfilling a disclosed reduction plan due to personal funding needs, with a potential further reduction of up to 1,213,014 shares (2% of total shares) within the next 12 months, depending on market conditions [9][10]. 4. Method of Equity Change - The equity change was executed through a block trade, and the information disclosure obligations have been met as per regulatory requirements [11][12].

键凯科技12月8日大宗交易平台出现一笔成交，成交量4.82万股，成交金额366.80万元，大宗交易成交价 为76.10元，相对今日收盘价折价9.44%。该笔交易的买方营业部为国都证券股份有限公司江苏分公司， 卖方营业部为平安证券股份有限公司泉州滨海街证券营业部。 证券时报·数据宝统计显示，键凯科技今日收盘价为84.03元，上涨1.58%，日换手率为0.75%，成交额为 3813.77万元，全天主力资金净流出274.60万元，近5日该股累计下跌0.63%，近5日资金合计净流出 596.66万元。 据天眼查APP显示，北京键凯科技股份有限公司成立于2001年10月09日，注册资本6065.07万人民币。 （数据宝） 12月8日键凯科技大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 4.82 | 366.80 | 76.10 | -9.44 | 国都证券股份有限 | 平安证券股份有限公司泉州 | | | | ...

Group 1 - The core transaction involved 48,200 shares of JianKai Technology, with a total transaction value of 3.668 million yuan, representing 8.77% of the total trading volume for the day [1] - The transaction price was 76.1 yuan per share, which is a discount of 9.44% compared to the market closing price of 84.03 yuan [1]

证券代码：688356 证券简称：键凯科技 公告编号：2025-042 北京键凯科技股份有限公司 一、本次权益变动基本情况 （一）信息披露义务人基本情况 | 姓名 | 吴凯庭 | | --- | --- | | 性别 | 男 | | 国籍 | 中国香港 | | 住所及通讯地址 | 福建省厦门市***** | | 是否取得其他国家或者地区的居留权 | 否 | （二） 本次权益变动情况 关于持股 5%以上股东权益变动触及 5%整数倍的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 如下： | 股东名称 | 股份性质 | | 本次变动前持有股份 | 本次变动后持有股份 | | | --- | --- | --- | --- | --- | --- | | | | 股数（股） | 占总股本 比例（%） | 股数（股） | 占总股本比 | | | | | | | 例（%） | | 吴凯庭 | 持有股份 | 9,145,847 | 15.08 | 9,097,647 | 15.00 | | | 其中：无限 ...

北京键凯科技股份有限公司 简式权益变动报告书 上市公司名称：北京键凯科技股份有限公司 股票上市地点：上海证券交易所 股票简称：键凯科技 股票代码：688356 信息披露义务人：吴凯庭 住所及通讯地址：福建省厦门市***** 权益变动性质：减少股份（大宗交易） 签署日期：2025 年 12 月 08 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民 共和国证券法》《公开发行证券的公司信息披露内容与格式准则第 15 号—权益变 动报告书》及其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》和《公开发行证券的公司信息披露内容 与格式准则第 15 号—权益变动报告书》的规定，本报告书已全面披露信息披露 义务人在北京键凯科技股份有限公司拥有权益的股份变动情况。截至本报告书签 署日，除本报告书披露的持股信息外，上述信息披露义务人没有通过任何其他方 式增加或减少其在北京键凯科技股份有限公司中拥有权益的股份。 四、本次权益变动 ...

Core Viewpoint - The company JianKai Technology (688356.SH) reported a shareholding change involving a reduction in shares held by Wu Kaiting, indicating a slight decrease in his ownership percentage [1] Summary by Sections - **Shareholding Change** - Wu Kaiting reduced his shareholding by 48,200 shares through a block trade on December 8, 2025, decreasing his ownership from 15.08% to 15.00% [1] - After the transaction, Wu Kaiting holds 9.0976 million shares, representing 15.00% of the company's total share capital, which is a significant threshold as it touches the 5% integer multiple [1]

Core Viewpoint - The launch event of SILKROSE, a brand under JianKai Technology, marks a significant milestone in showcasing China's innovative strength in medical beauty materials, particularly with the introduction of PEG cross-linked hyaluronic acid gel [1][7]. Group 1: Event Overview - The event was co-hosted by SILKROSE and Beijing Shouxi Lige, featuring industry experts and leaders discussing the future of the medical beauty industry under the "Healthy China" strategy [3]. - The event emphasized the importance of independent innovation in medical materials technology to promote sustainable development in the medical beauty sector [3]. Group 2: Product Innovation - SILKROSE is positioned as a systematic solution to address pain points in the traditional filling market, aiming to reshape the industry landscape [4]. - The PEG material technology utilized in SILKROSE represents a significant innovation, transitioning the medical beauty industry from "scale growth" to "value innovation" [4]. Group 3: Clinical Application Standards - The new clinical application standards for SILKROSE were presented, highlighting the need for filling materials to provide both dynamic integration and static support [5]. - SILKROSE offers a comprehensive solution for clinical practitioners, including injection techniques and dosage planning, transforming material science innovation into standardized clinical practices [5]. Group 4: Strategic Partnerships - A strategic partnership was established between SILKROSE and Beijing Shouxi Lige, with the latter being awarded the title of "Chief Medical Guidance Expert," enhancing collaboration in the industry [5]. - This partnership exemplifies the synergy between production, academia, research, and application, aiming to set new industry benchmarks [5]. Group 5: Technological Breakthroughs - SILKROSE, as the first domestically developed injectable PEG cross-linked hyaluronic acid gel, underwent nine years of research and received NMPA Class III medical device certification [7]. - The PEG cross-linking technology ensures no residuals remain post-degradation, offering high biocompatibility and a natural filling effect [7]. Group 6: Industry Vision - The event transcended product promotion, fostering discussions on the future of the medical beauty industry and the role of technological innovation in driving industry upgrades [8]. - SILKROSE aims to contribute to a safer, more professional, and healthier development of the medical beauty industry, aligning with the "Healthy China" initiative [8].

Core Points - The company, JianKai Technology, announced the appointment of Mr. Chen Bin as the Secretary of the Board [1] Group 1 - JianKai Technology made an official announcement regarding the hiring of a new board secretary [1]

证券代码：688356 证券简称：键凯科技 公告编号：2025-040 北京键凯科技股份有限公司 关于完成董事会换届选举及 （一）董事选举情况 2025 年 11 月 18 日，公司召开 2025 年第二次临时股东会，通过累积投票制的方式 选举 XUAN ZHAO 先生、韩磊女士、张如军女士、王庆彬先生、LIHONG GUO 女士、 吴伟京女士担任公司第四届董事会非独立董事，选举林雯女士、张杰女士、高巧莉女士 担任公司第四届董事会独立董事。本次股东会选举产生的六名非独立董事和三名独立董 事共同组成公司第四届董事会，任期自股东会审议通过之日起三年。 上述第四届董事会董事简历详见公司于 2025 年 10 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于董事会换届选举的公告》（公告编号:2025-033）。 聘任高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》（以下简称" ...